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Executive summary 
This report offers a new perspective on the legacy of Dolly the sheep by tracing the 
chain of experiments within which she was produced as the first cloned mammal in 
1996. We argue that the media storm that followed her birth, with intense debates 
about the ethics of escalating the technology and obtaining exact copies of humans, 
obscured the underlying motivations of the experiments and the important role 
that the cloning technology has later played in stem cell research and regenerative 
medicine. By adopting a historical perspective, we show that Dolly should be placed 
within an established research project that started in the early-to-mid 1980s and 
sought to genetically modify – rather than copy – farm animals. She was not the 
start, neither the conclusion of the project, this suggesting that we need a broader 
framework to fully capture her impact. When, instead of Dolly, we focus on the genetic 
modification research within which she was produced, the ramifications of that 
project go as far as recent efforts to sequence the genome of the pig and use that 
information as a model of human biology and disease. We conclude that historical 
studies may help to chart the long-term impact of scientific projects, especially when 
they have been funded by different administrative agencies, due to their outputs 
spanning disciplines and species.
Front cover image courtesy of the Roslin Institute.
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1. Introduction
Dolly the sheep is regarded as one of the most iconic 
experimental animals of recent biomedicine. In July 
1996, she became the first mammal to be born after the 
introduction of the cell nucleus of an adult sheep into an 
egg devoid of its nucleus (in normal reproduction, the egg 
nucleus contains half of genetic material of the newborn – 
coming from the mother – while the other half is provided by 
the father’s sperm cell nucleus). Due to the lack of nucleus in 
her egg, Dolly was not a pool of her two parents: she rather 
shared 100% of genetic material with another sheep – the 
donor of the adult cell nucleus that had been transferred to 
the egg. She was thus a clone or a genetic copy of an existing 
adult sheep.1
Dolly was born at the Roslin Institute, a scientific centre six 
miles south of Edinburgh with a long tradition of animal 
breeding research that was largely supported by the UK 
Biotechnology and Biological Sciences Research Council 
(BBSRC) and its predecessor public funding bodies. In 
February 1997, days before the landmark publication in 
Nature (Wilmut et al, 1997), the scientists involved were 
surprised by an unexpected report in The Observer – they 
had intended to keep Dolly secret until the scientific article 
was out. The Roslin Institute then decided to organise a 
public presentation that attracted an unprecented level of 
media attention and stimulated far-reaching debates about 
the use of the technology – named ‘nuclear transfer’ within 
the scientific community and ‘cloning’ by the media. Given 
that Dolly was a genetic copy of another sheep, much of 
the public debate focused on the possibility of replicating 
the experiment in other species (Suk et al, 2007). The media 
and their audiences regarded with reservation this potential 
spread of the technology, especially to higher animals. In 
the months following Dolly’s presentation, a consensus grew 
among scientists, society and policy-makers on the necessity 
of setting ethical boundaries and regulating the technology 
in order to avoid the potential cloning of humans.2 
These debates were mainly speculative and addressed 
the imagined future uses of nuclear transfer (Holliman, 
2004). Media and public imagination concealed both the 
limitations of the technology at the time of Dolly’s birth 
and, more crucially, the reasons why the Roslin researchers 
wanted to clone a sheep. While Dolly is an almost universally 
known scientific figure, the logic and motivations behind 
her creation are rarely brought up, even within the scientific 
community. This asymmetry of knowledge becomes 
more pressing when we look at the experiments that both 
preceded and succeeded Dolly: cloning was not the final 
objective of the Roslin scientists and in the months following 
the public presentation, they produced additional sheep that 
went largely unnoticed. Instead of being copies of adult cells, 
these sheep had been genetically modified to incorporate 
features that were absent in their ancestors and valuable 
from a commercial viewpoint. In other words, the cloning 
of Dolly was not an end in itself, but a means for producing 
sheep that possessed unique genetic modifications rather 
than being identical to other animals.
Dolly’s history has been particularly difficult to trace due to 
this lack of knowledge. Given the secrecy of her birth and 
subsequent simplification of media accounts, only a small 
group of insiders know the complex chain of experiments 
that sorrunded her creation. Dolly and nuclear transfer were 
neither the beginning nor the end of these experiments. 
With this in mind, in 2015 the BBSRC and the University of 
Edinburgh funded Historicising Dolly, a project to place the 
cloned sheep within a broader context of animal genetics 
research. Throughout 18 months, we organised a Collective 
Memory Event in which we gathered the scientists and 
stakeholders involved in the cloning experiments, recorded 
their recollections and made them publicly available in 
written and electronic form (Myelnikov & Garcia-Sancho, 
2017)3.  We also published two academic papers that 
reconstructed the line of research through which Dolly was 
produced and showed that the first experiments can be 
dated back to the early-to-mid 1980s (García-Sancho, 2015; 
Myelnikov, forthcoming). Our work portrays Dolly as the 
product of a long-term scientific project that was funded 
over more than a decade by the BBSRC and its institutional 
predecessors, the Agricultural Research Council (ARC) and 
the Agricultural and Food Research Council (AFRC) see 
table overleaf. The aim of that project was to genetically 
modify farm animals and use them to produce drugs for the 
treatment of human conditions. Cloning and nuclear transfer 
were just tools to achieve genetic modification rather than 
the ultimate objective of the experiments.
1 This adult sheep was not alive at the time of Dolly’s birth, since scientists decided to use the nucleus of an adult cell that had been frozen and preserved years after the donor’s death. Sharing 100% of genetic 
material meant that Dolly looked much alike the donor of this frozen cell, although behaviour and other characteristics are not determined by genes only: they rather derive from complex interactions between 
genes and the environment.
2 See, for example, “The cloning of animals from adult cells,” fourth report of the UK Parliamentary Committee on Science and Technology, Session 1996-1997.
 See http://www.publications.parliament.uk/pa/cm199798/cmselect/cmsctech/1039/103903.htm (last accessed May 2017).
3 Electronic version available at http://www.research.ed.ac.uk/portal/en/publications/dolly-at-roslin(59056ace-04a4-4019-b033-936cd7297f71).html. The third author of this report, James Lowe, is currently 
investigating the history of the pig genome project, an international initiative that was conducted between 1990 and 2012. The Roslin Institute was a major contributor to this initiative and developed some 
of the technologies that made it possible out of the same project within which Dolly was produced. Lowe’s work is supported by an ERC Starting Grant led by Miguel García-Sancho, the Principal Investigator of 
the Historicising Dolly project. For more information about the ERC grant see www.stis.ed.ac.uk/transgene (both links last accessed May 2017).
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Building on our historical research, this report reflects on 
Dolly’s legacy. Our work has enabled us to look in detail at 
the events that preceded Dolly and place the significance 
of her birth beyond the confines of cloning and the 
public debate it fostered. In order to capture this broader 
significance, it is essential to move the level of analysis out of 
Dolly and the nuclear transfer technology. In our research, we 
did not directly address the Dolly furore of 1997. Instead, we 
shifted our object of inquiry a decade back and investigated 
the previous genetic modification project. This enabled us 
to see a set of technologies, animals and goals within which 
Dolly and cloning were essential but rather time-specific 
parts. When Dolly is assessed against this wider horizon, the 
ramifications of the research that preceded her birth become 
far-reaching.
In what follows, we will use this interpretative framework 
to analyse what happened after Dolly. We will show that 
the impact of this piece of science – on both medicine and 
agriculture – can be seen more clearly when taking into 
account the project that led to Dolly’s creation. To this end, 
the next section will review the long-term line of research 
that shaped the cloning of Dolly, the so-called pharming 
project. This project culminated at the Roslin Institute, 
but started and consolidated at two of its institutional 
predecessors, the Animal Breeding Research Organisation 
(ABRO, 1947-86) and the Institute of Animal Physiology 
and Genetics Research (IAPGR, 1987-93, see table below). 
We will then look at the main ramifications of the pharming 
project and how it informed research fields that are still 
highly influential in Roslin and beyond: stem cell science 
and animal genome analysis. The report will close with 
some considerations about the utility of history in scientific 
planning and policy. We will argue that historical research 
may show scientific continuities across time periods and 
institutional spaces that are administered by different 
funding agencies.
Institution
Animal Breeding Research 
Organisation (ABRO), 
1947-86
Institute of Animal 
Physiology and Genetics 
Research (IAPGR), 
1987-1992
Roslin Institute, 1993 
onwards
Funding agency
Agricultural Research Council 
(ARC), 1931-83
Agricultural and Food Research 
Council (AFRC), 1984-1993
Biotechnology and Biological 
Sciences Research Council 
(BBSRC), 1994 onwards
Research project examples
Hereford breed (long-term 
programme involving 
crossing of various 
generations of cows)
Causes of scrapie (sheep 
disease)
Pharming (production of 
transgenic sheep)
PiGMaP (mapping of porcine 
genome)
Pharming (production of 
transgenic sheep)
PiGMaP (mapping of porcine 
genome)
Celebrity animals
None
Tracy (1990, genetically 
modified sheep)
Megan and Morag (1995, 
sheep cloned from embryo 
cells)
Dolly (1996, sheep cloned 
from an adult cell)
Polly (1997, both 
transgenic and cloned 
sheep)
Summary of  the different institutional antecedents of the Roslin Institute and BBSRC
Due to the lack of nucleus in her 
egg, Dolly was not a pool of her 
two parents: she rather shared 
100% of genetic material with 
another adult sheep.
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Figure 1: A scheme of the nuclear transfer technology. 
Courtesy of Encyclopaedia Britannica, Inc., copyright 2015 and used with permission.
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2. Dolly in history: genetic engineering and the Rothschild reform
The birth of Dolly was a step in a long-term research project 
that started in 1984 and culminated in 1997 with the 
birth of another sheep called Polly.4  The first institutional 
home of this project was the Animal Breeding Research 
Organisation (ABRO), an institution that had been set 
in Edinburgh in 1947 with the aim of creating scientific 
knowledge to improve the commercial yield of livestock. 
ABRO had benefitted from sustained funding by the 
Agricultural Research Council (ARC), a body of the British 
Government that had been established in the 1930s and, 
following the persistence of rationing policies after World 
War II, had developed a UK-wide network of experimental 
stations to improve the productivity of agriculture (DeJager, 
1993; Thirtle et al, 1991; Vernon, 1997). During its early 
years, ABRO enjoyed growing popularity among farming 
associations and designed extended, multi-generational 
breeding programmes that improved the health and food 
production of pigs, cattle and sheep (see table above). 
However, a number of socio-political transformations in 
Britain led to growing government scepticism about the 
utility of these contributions.
The changes started in 1971 with the publication of the 
Rothschild Report, commissioned by Edward Heath’s 
Conservative government with the aim of improving the 
efficiency of public administration. The report was authored 
by Victor, 3rd Baron Rothschild, a former chairman of the 
ARC who had subsequently served as head of research of 
Shell, the oil-and-gas company. Controversially, Rothschild 
argued that publicly-funded research in the UK had served 
abstract, academic interests rather than the real needs of 
the country. He proposed a customer-contractor principle, in 
which government departments would decide how to spend 
a large proportion of the Treasury’s budget for scientific 
research (Calver & Parker, 2016). This Government budget – 
called the science vote – had traditionally been split among 
the research councils and further distributed to universities 
and institutes in the form of grants. The councils’ research 
institutes had been asked to plan their research activities 
over long periods of time and received block grants that were 
reviewed against scientific progress. It had been the ultimate 
responsibility of the scientists in charge of the institutes to 
decide how to spend the grants on a day-to-day basis.
After the implementation of the Rothschild model, the 
research councils’ budgets were split between the science 
vote – that could still be directly spent in grants – and funds 
that needed to be requested to ministries and government 
departments. These public bodies would act as informed 
customers and support applied projects in which the research 
institutes would play the role of contractors. The funded 
projects were necessarily shorter-term and assessed against 
the timely delivery of concrete outputs, not just scientific 
progress. Rothschild was one of the first persons to apply the 
corporate term ‘R&D’ to publicly funded science. His model 
was founded on a sharp distinction between ‘fundamental’ 
and ‘applied’ research (Rothschild, 1972), with the former 
being left untouched by his reforms but given a substantially 
lower proportion of the research councils’ funds: after the 
Rothschild Report, only about half of those funds could be 
spent on long-term projects with purely scientific objectives. 
The expenditure of the other half was conditioned to the 
formalisation of applied research contracts between the 
government, the councils and their institutes.
The agricultural sciences were one of the priority areas of 
Rothschild’s reforms. His experience as head of the ARC 
had persuaded him that this institution was one of the 
main culprits of the perceived lack of impact of British 
science (Parker, 2016). Due to this, a significant part of the 
ARC budget was transferred to the Ministry of Agriculture, 
Fisheries and Food (MAFF), while other public bodies enjoyed 
greater flexibility to apply the customer-contractor principle 
– the Medical Research Council (MRC) managed to reverse it 
and recover direct control of most of its budget in the early 
1980s (de Chadarevian, 2002, ch11; Wilkie, 1991, ch5). By 
that time, British society had substantially changed and the 
nutrition problems derived from World War II had long been 
forgotten. This made the ARC’s scientific agenda, which 
was still significantly framed in augmenting the amount 
of food via animal and plant breeding, unappealing to an 
increasingly affluent and urban population.
Margaret Thatcher’s election as Prime Minister in 1979 
deepened Rothschild’s reforms. Thatcher had been 
Secretary of State for Education and Science under Heath’s 
Government and, despite being ambivalent about the 
1971 Report, she saw in Rothschild’s dual funding system 
an opportunity to keep supporting fundamental research 
– even with decreasing budgets – while reducing the cost 
and increasing the impact of applied science (Agar, 2011). 
Within agricultural research, this meant downsizing the 
4  In this report, we will offer a very brief outline of the scientific project that led to the birth of Dolly, Polly and other experimental sheep. For a broader discussion of this project, its establishment and 
development up to the mid-1990s see García-Sancho, 2015.
5  One of our published papers offers a detailed analysis of both the ARC and ABRO’s response to the political turmoil of 1970s and 80s Britain (Myelnikov, forthcoming). It suggests that the ARC’s decision of 
focusing on a few strategic lines of research preceded any dramatic impact of Rothschild and Thatcher’s reforms on its budget.
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multi-generational breeding programmes requiring large 
and expensive amounts of farmland, and replacing them 
with more selective variation of a few animal species. In 
1982, the ARC produced a strategic briefing that reflected 
this new philosophy and argued against a blanket cut of 
their breeding programmes in the face of financial hardship. 
Instead, the shrinking resources would be devoted to a 
few ‘priority areas’ with the potential of transforming the 
practice of breeding (ARC, 1982).5 Shortly after this decision, 
in response to pressure from multiple advisory committees, 
the ARC changed its name into Agricultural and Food 
Research Council (AFRC), emphasising its move away from 
production and into areas such as food processing or storage.
The ARC’s plans originally involved reducing ABRO’s activity 
by 80%. However, intervention from the farming sector, 
media, MPs and MAFF – now a key customer – meant the 
cuts were in fact 50%. ABRO’s experimental farms outside 
Scotland were sold, early retirements implemented, some 
staff were made redundant and the funding of its research 
teams and programmes was dramatically reduced. This 
made clear that ABRO’s research strategy needed to be 
redesigned in line with its smaller stock of land, animals and 
staff. ABRO’s internal reports describe this transition period 
as a ‘dramatic time’ that ‘inevitably left its scars.’ They also 
acknowledge that some researchers interpreted the reforms 
as a “betrayal” of their hard work.6
In 1982, Roger Land was appointed as the new director of 
ABRO. He was in charge of navigating the ARC cuts and 
decided to focus on genetic engineering, which was then 
regarded as an innovative field with potential of transforming 
traditional breeding research. The techniques to cleave 
and reassemble genetic material had been invented in the 
mid-1970s under the name of recombinant DNA and tested 
in microorganisms (Rasmussen, 2014; Yi, 2015). Shortly 
before Land’s appointment, they had been exported to mice 
and their application to agriculture had triggered growing 
expectations (Smith et al, 1986). In its strategic briefing, 
the ARC had set genetic engineering of plants as one of 
its priority areas. Land saw the expansion of this technique 
to animals as a niche and established a molecular biology 
programme at ABRO that was headed by two new recruits: 
Richard Lathe, a former worker of the French biotechnology 
company Transgéne, and John Clark, a geneticist with 
experience in the MRC Clinical and Population Cytogenetics 
Unit of the neighbouring University of Edinburgh.
The new programme materialised in a number of specific 
lines of research during the mid-1980s. One of the 
pioneering lines was called the pharming project and 
involved the use of recombinant DNA to produce genetically 
modified sheep. These sheep would carry in their DNA an 
extra, foreign gene that was absent in their parents. The 
additional gene would enable the modified sheep to express 
in their milk proteins to treat human illnesses.7 Up to then, 
most of the genetic modification of farm animals had 
focused on increasing their size and therefore the amount of 
food they produced via inserting extra copies of the growth 
hormone gene – with little progress. With the pharming 
project, Lathe and Clark saw a new area of application that 
would enable them to commercialise the proteins in the 
form of drugs for human consumption. To this end, ABRO 
created a start-up biotechnology company called Caledonian 
Transgenics and soon renamed Pharmaceutical Proteins 
Limited, or PPL (Clay & Goldberg, 1997; Fransman, 2001).8
The pharming project became one of the few lines of 
research that survived increasing financial stringency. In 
1987, the same year Caledonian Transgenics was founded, 
ABRO was forced to merge with another AFRC-supported 
institution, the Institute of Animal Physiology in Babraham, 
Cambridgeshire. This resulted in a large organisation called 
the Institute of Animal Physiology and Genetics Research 
(IAPGR), with two autonomous stations, one located in 
Edinburgh and the other in Babraham. The merger involved 
further redundancies of technical and administrative staff, 
as well as the eventual relocation of the Edinburgh Research 
Station from Edinburgh University’s natural science campus – 
the King’s Buildings – to Roslin. However, the pharming team 
benefitted from the Transgenic Animal Programme, a new 
funding stream the AFRC created to support work on genetic 
modification and stem cell research. By that time, Lathe 
6 Quotes from ‘‘Comment’’, ABRO Annual Report—January 1983, p. 3 and ‘‘Preface’’, ABRO Annual Report—January 1986, p. 1. Wellcome Trust Towards Dolly archival project, Edinburgh University Library 
Special Collections, reference EUA IN23/1/1/2. 
7 For a detailed description of the pharming project, its development and the events leading to its implementation see García-Sancho, 2015: 291ff. See also R. Lathe: “Molecular tailoring of the farm animal 
germline,” ABRO Annual Report – January 1985, pp. 7-10. Wellcome Trust Towards Dolly archival project, Edinburgh University Library Special Collections, reference EUA IN23/1/1/2.
8 The establishment of Caledonian Transgenics was supported by venture capital raised by the Scottish Development Agency, a public body now called Scottish Enterprise and devoted to promote new business 
initiatives in Scotland (Myelnikov, forthcoming). The pharming approach – also known as biopharming – was also applied to plants and mobilised both scientific and commercial expectations (Milne, 2012).
In the turmoil of 1980s Britain, 
genetic engineering was 
regarded as an innovative field 
with potential of transforming 
traditional breeding research 
and making it less resource-
intensive.
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had left Edinburgh and Clark become head of the molecular 
biology programme.
With this support, Tracy, the first genetically modified sheep 
to make significant quantities of a human protein, was born 
in Roslin, in 1990. Her DNA contained an extra gene that 
produced alpha-1-antitripsin (AAT), a protein used in the 
treatment of emphysema and cystic fibrosis. The production 
of the sheep was rather cumbersome and involved the 
injection of the foreign gene into Tracy’s embryo. This 
9  For an account of Tracy’s creation, see the printed volume of our Collective Memory Event, which names the full range of scientists and professionals involved in her creation (Myelnikov and Garcia-Sancho, 
2017: 5ff). Also available at http://www.research.ed.ac.uk/portal/en/publications/dolly-at-roslin-a-collective-memory-event(59056ace-04a4-4019-b033-936cd7297f71).html
Figure 2: A schematic representation of the pharming project. 
ABRO Annual Report – January 1986, p.22, reprinted with permission from Edinburgh University 
Main Library.
Tracy, the first transgenic sheep produced in Roslin. 
Courtesy of the Roslin Institute. 
process required additional expertise in the pharming team, 
in the form of tissue culture and veterinary professionals 
who surgically extracted the embryo, performed the gene’s 
microinjection and re-implanted it into a surrogate mother.9 
Due to this, although the levels of protein expression in 
Tracy’s milk were beyond the expectations, its production 
process was not suitable for an industrial development that 
would enable PPL to mass-produce drugs. The pharming 
project started diversifying in search of solutions and this led 
the team to move into new research areas.
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3. The ramifications of the pharming project
The Roslin scientists reacted in different ways to the 
difficulties in creating Tracy. Whereas some developed 
alternative techniques to produce genetically modified 
sheep and achieve the objectives of the pharming project, 
others applied the expertise that the project had already 
produced to new research areas. In what follows, we will 
focus on cloning as an example of the former strategy 
(develop alternative techniques) and animal genomics as 
representative of the latter (exportation of existing expertise 
to new fields). The most visible outcome of the pharming 
project was the cloning of Dolly in 1996, given that the drugs 
for human consumption it originally envisaged were never 
delivered on a commercial scale. However, towards the late 
1990s, the same nuclear transfer technology that enabled 
the birth of Dolly started playing a crucial role in stem cell 
research and human regenerative medicine. This and the 
sequencing of the genome of farm animals such as cows 
and pigs can be seen as the main legacy of the pharming 
project; one that has been eclipsed by the publicity around 
the cloning of Dolly.
3.1  Cloning and stem cell research
Following the birth of Tracy, the pharming team started 
looking for a method that would increase the level of both 
successful birth and assimilation of genetic modifications 
by newborn transgenic animals. The team concluded that a 
promising avenue was introducing the genetic modification 
before rather than after the fertilisation of the sheep egg, 
thus avoiding embryo microinjection. A favoured procedure 
within this approach was using stem cells that had not 
differentiated during the development of the animals from 
embryo to adult form. If those cells were genetically modified 
and inserted into an egg, they would have the sufficient 
plasticity to express the extra, foreign genes during the 
development of the newborn animal. The production of 
genetically modified mice had been considerably eased and 
improved with the use of stem cells in the early-to-mid 1980s 
(Myelnikov, 2015, chs4-5). This type of cells were yet difficult 
to isolate in sheep.
The first role of nuclear transfer in Roslin was to complement 
the stem cell approach. The technique would enable the 
insertion of the genetically modified stem cell nucleus 
into an oocyte – unfertilised egg – thus producing the 
transgenic sheep. Ian Wilmut, a developmental biologist 
who had previously worked on embryo transfer to improve 
the birth rate of cows, sheep and pigs, was the person in 
charge of the development of this technology. He teamed 
up with Keith Campbell, a cell biologist who joined Roslin 
in 1991 to investigate how normal development could 
be reprogrammed. The objective of both scientists was 
to transform the stem cell nucleus into an embryo cell 
that could be assimilated by the oocyte and trigger the 
development of a newborn sheep (Myelnikov & Garcia-
Sancho, 2017: 9ff).
The first role of nuclear 
transfer in Roslin was to ease 
genetic modification rather 
than producing exact copies 
of sheep.
Due to the intricacies of this developmental process, 
Wilmut and Campbell decided to first test the technology 
without introducing any genetic modification. Out of 
these experiments, two sheep called Megan and Morag 
were born in 1995. Unlike Tracy, Megan and Morag were 
cloned animals, in the sense that their genetic material was 
an exact, unaltered copy of another sheep. However, the 
cell nuclei from which these two clones had been created 
belonged to a sheep embryo rather than an adult animal. 
This choice of nuclei was motivated by the difficulties of 
isolating stem cells after full sheep development: Wilmut 
and Campbell settled on embryo cells as the most equivalent 
available material (Campbell et al, 1996). By the time 
of these births, the IAPGR had been disbanded, and the 
Babraham and Edinburgh Research Stations become 
independent institutions again. The Edinburgh Station 
acquired its current denomination of Roslin Institute in 1993 
and one year afterwards, the AFRC absorbed the biological 
component of the Science and Engineering Research Council 
to form the BBSRC.
The birth of Dolly was a more challenging interrogation 
of the nuclear transfer technology. Wilmut and Campbell 
managed to completely reverse and reprogram the 
development of an adult cell once inserted into the oocyte. 
This showed that the technology could work with any cell 
and overcame the difficulties of both working with embryos 
and obtaining sheep stem cells. The cell from which Dolly 
was cloned belonged to the mammary gland of an already 
deceased sheep. It had been isolated and frozen by the 
company PPL, which since its foundation had formed a team 
of experts in cell culture and preservation with the aim of 
accelerating the delivery of the pharming project. Dolly was 
kept secret for six months after its birth in July 1996, in order 
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to protect the novelty of the Nature publication (Wilmut 
et al, 1997). After her presentation, the media furore arose 
and Wilmut gradually became the spokesperson for the 
experiments and, in the eyes of the public, the father of Dolly 
the sheep.
Dolly, as the first genetic copy of a fully developed sheep, 
superseded the popular fascination of Megan and Morag. 
The media storm, along with the increasing attention to 
Wilmut, focused the public debate on cloning and de-
emphasised the other objectives of the pharming team. This 
was helped by the semi-autonomous status of the nuclear 
transfer experiments from a financial viewpoint. While the 
BBSRC funded the core of the pharming project – the genetic 
modification of sheep, as well as some early work on cell 
culture – research on nuclear transfer required additional 
support from PPL and the Ministry of Agriculture, Fisheries 
and Food (MAFF). This led the media and their audiences 
to regard cloning as a self-contained project rather than 
as a means for genetic modification. The group in charge 
of the nuclear transfer technology became increasingly 
independent from the pharming team and acquired its 
own interests, such as embryo development and stem cells. 
Furthermore, MAFF was not keen on being identified with 
genetic modification at a time in which the debate around 
GM crops was reaching its climax (Wynne, 2001).
A few months after the presentation of Dolly, six other sheep 
were born in Roslin. They were both cloned and genetically 
modified, in the sense that their embryos had been produced 
through the transfer into an oocyte of a cell nucleus to 
which a foreign gene had previously been added. The most 
promising of them was called Polly, a sheep that secreted 
in its milk the protein Factor IX, used in the treatment of 
haemophilia. This protein was derived from the insertion of 
an extra, human gene in Polly’s DNA (Schníeke et al, 1997). 
Despite Polly representing the culmination of the pharming 
project, its birth went largely unnoticed: the media discussion 
remained focused on Dolly and cloning, without any 
significant mention of other sheep or the phenomenon of 
genetic modification. It is rather laborious to find descriptions 
or pictures of Polly, even in the research reports and internal 
publicity of the Roslin Institute.
Polly’s birth was closely monitored by PPL, in the hope that 
Factor IX could be recovered from the milk and transformed 
into a commercial drug for human consumption. However, 
as in the case of Tracy, this development was hindered by 
practical problems: the levels of protein expression were 
tight for industrial drug production and the company found 
innumerable difficulties in clinical trials (Myelnikov & Garcia-
Sancho, 2017: 19ff). In the face of this, the Roslin Institute 
created another start-up company to expand the commercial 
horizons of the pharming project. The new company, 
named Roslin BioMed and founded in 1997, would explore 
alternative applications of both the genetic modification and 
nuclear transfer technologies. PPL retained the specific patent 
that allowed the development of drugs from milk proteins.10 
Shortly after the creation of Roslin BioMed, a team at the 
University of Wisconsin isolated the first human embryonic 
stem cells. These cells were derived from human embryos 
Figure 3: The team in charge of the development of the nuclear transfer 
technology (in the top row, Wilmut is second from the left and Campbell 
first from the right). Courtesy of the Roslin Institute.
Megan and Morag. Courtesy of the Roslin Institute.
10 After numerous attempts with sheep and pig, no commercial applications were found out of the pharming project and PPL ceased to exist in the mid-2000s (Reid and Smith, 2006). 
 Other companies, namely Pharming in the Netherlands, commercialised human milk products out of this procedure. In 1990, Pharming produced Herman the bull, the first genetically modified bovine 
(Myelnikov and Garcia-Sancho, 2017: 7).
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and had the same properties as in mice and sheep: due to 
their plasticity, they could become any tissue in adult form. 
The cells’ plasticity meant that they could potentially be 
used in human medicine to regenerate any damaged tissue. 
Following a cardiac arrest or knee injury, patients could be 
inoculated with stem cells around the affected area, and they 
would develop into heart muscle or cartilage (Thomson et al, 
1998). The efficiency of the new therapy was even greater 
if an adult cell nucleus from the patient was obtained and 
inserted into an oocyte to form an embryo. Sourcing stem 
cells from that embryo helped avoid immune rejection after 
patient’s inoculation.
The Wisconsin team was funded by the US pharmaceutical 
company Geron. This company saw in the nuclear 
transfer procedure developed by Wilmut and Campbell an 
opportunity of complementing regenerative therapies with 
embryo cloning of patients’ cells. In 1998, the year the 
Wisconsin group isolated the first stem cells form human 
embryos, Geron decided to acquire Roslin BioMed – only a 
few months after the foundation of the latter company. In 
exchange, Geron provided a five-year grant to the Roslin 
Institute that would fund any aspect in the investigation 
of cell development. This led Roslin to become a reference 
centre in developmental biology and stem cell research, and 
gradually shifted Wilmut’s career from agricultural science to 
regenerative medicine.11 
Yamanaka at the University of Kyoto developed a technique 
to produce pluripotent stem cells without the necessity of 
creating embryos. That same year, Wilmut announced that 
he would stop using cloning and became a founding Director 
of the Edinburgh Centre for Regenerative Medicine (Wilmut 
et al, 2011). Unlike the Roslin Institute, this new centre 
was focused on human medicine and fell into the remit of 
the MRC rather than the BBSRC. The association of stem 
cells with human patients led regenerative medicine to be 
identified with the MRC and partially eclipsed the role of the 
BBSRC in the emergence of this new field.
3.2  Farm animal genomics
The advent of genomic techniques in Edinburgh has roots 
in both the older animal breeding tradition of ABRO and 
the newer molecular orientation introduced following 
the reconfiguration of the programme of research at 
that institution in the early 1980s. As discussed above, 
financial stringency threatened ABRO, to the extent of this 
institution fearing closure. Within this uncertain context, 
informal debates between the Edinburgh scientists centred 
on the nature and direction of the envisaged research 
reconfiguration (Myelnikov & Garcia-Sancho, 2017: 
8ff). Some, such as Clark’s postdoctoral researcher, Alan 
Archibald, proposed giving an autonomous role to genome 
analysis of farm animals. However, until the late 1980s this 
line of research was rather subordinate to the pharming 
project: DNA mapping techniques were seen as tools for 
identifying genes that would produce transgenic animals.
In the aftermath of ABRO’s reconfiguration, Archibald was 
successful in obtaining a research commission from MAFF 
to investigate the genetics of halothane sensitivity in pigs, 
having previously worked on cattle. Halothane is a veterinary 
anaesthetic that had been found to be connected to Porcine 
Stress Syndrome (PSS). During the early and mid-1980s, PSS 
had become a major problem in the food industry, leading 
pigs to suddenly die, and their meat to become pale, soft 
and exudative, and therefore unattractive to consumers. This 
problem had partially been caused by breeding techniques to 
reduce back fat, driven by consumer demand for leaner pork 
meat in Europe and North America from the second half of 
the 20th century. 
In theory, using halothane as a test could enable breeding 
companies and farmers to exclude susceptible – halothane 
sensitive – pigs from breeding. However, given the 
impracticalities of this test and the fact that this was a 
recessive trait – it could be transmitted to offspring by 
The US pharmaceutical 
company Geron saw in the 
nuclear transfer procedure an 
opportunity of complementing 
regenerative therapies with 
embryo cloning of patients’    
cell nuclei.
By the end of the 20th century, nuclear transfer was thus 
recast from a procedure to make genetically modified 
animals to a means for obtaining human embryonic stem 
cells. The scaling-up of cloning from sheep to humans was 
finally achieved, but not in the way the media and their 
audiences imagined. Far from being used as a reproductive 
technique – to create babies identical to adults – cloning 
was a source for obtaining embryos that would provide 
compatible stem cells for patients. In 2008, Shinya 
11 Campbell, on the contrary, continued producing genetically modified animals. He became a PPL scientist and led further attempts to commercialise the pharming procedure in the US. In 1999, he moved to 
the University of Nottingham and died prematurely thirteen years afterwards.
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apparently non-sensitive pigs – alternative means of 
removing this characteristic were sought. As with the human 
medical geneticists who in the mid-1980s attempted to 
identify and map disease genes (Lindee, 2005), it became a 
pressing matter for the livestock and breeding industries to 
identify the genetic basis of halothane sensitivity and PSS.
Halothane sensitivity was identified as a single-locus trait – 
i.e. connected to one gene and occupying a defined region 
of the chromosome. Of particular interest to the geneticists 
was the relationship of this gene with nearby genes, or linked 
genes that tend to be inherited together. If the relationships 
between the halothane sensitivity locus and other loci in 
the same chromosome could be established, then inferring 
susceptibility to PSS would be easier. The detection of 
linked genes or other biochemical markers – observable 
characteristics connected to these genes – could lead to the 
development of a more practical test than the application 
of halothane, and therefore allow farmers and breeding 
companies to eliminate the trait from herds. 
With a number of researchers working on this problem 
across Europe and North America, linkage relationships were 
established, the condition was attributed to a particular 
mutation in a specific gene and biochemical tests for 
blood markers were developed. This offered breeders the 
opportunity to manage the responsible gene, and eradicate 
it if they so wished (O›Brien & MacLennan, 1991; O’Brien 
& Ball, 2013; Otsu et al, 1991). Thus the mapping of the 
linkage relationships between genes had enabled the 
livestock industry to put into practice a more precise and 
effective means of selection for animal breeding. Combined 
with the inspiration of the nascent work in human genetic 
mapping (Harper, 2008, ch7), this provided impetus for the 
Edinburgh-based researchers and their colleagues to press for 
a more general mapping approach to the pig genome. 
A substantial part of this approach crystallised in the first 
European farm animal genetics conference, held in Edinburgh 
in 1989. In this conference, many of the participants in the 
work on halothane sensitivity helped to develop a plan to 
research two types of pig genome map: 1) a genetic map 
showing the position of linked genes on the chromosomes 
and 2) a physical map dividing the chromosomes into an 
ordered set of overlapping DNA fragments. Archibald and 
Chris Haley, of the Edinburgh Research Station (ERS) of the 
IAPGR, subsequently applied for and obtained grants from 
the AFRC and MAFF, in collaboration with their colleagues at 
the Cambridge Research Station, Elizabeth Tucker and Ross 
Miller.
In addition to this, a proposal was developed for a project 
named PiGMaP, with the cooperation and support of Hervé 
Bazin, a scientific staff member in the Directorate-General for 
Science, Research and Development of what was then the 
Commission of the European Communities (CEC). PiGMaP 
co-ordinated 11 European laboratories and obtained 1.2 
million ECUs funding from the BRIDGE programme, part 
of the Second Framework Programme of the European 
Commission. The proposal started in 1991 and was based on 
flexible collaboration between the participants, following the 
model of European Laboratories Without Walls (ELWW).12 
In Edinburgh, the work involved genetic linkage mapping 
12 A.L. Archibald and E.M. Tucker: “Genome analysis,” IAPGR – Annual Report 1990-91, pp.126-27 Wellcome Trust Towards Dolly archival project, Edinburgh University Library Special Collections, 
 reference EUA IN23/3/1/1.
Figure 4 left: First meeting of the PiGMap project, held in Edinburgh in 1991 – Alan Archibald is wearing a Scottish kilt on the left. Right: The project’s logo. 
Courtesy of A. Archibald.
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based on crosses between reference families of Large White 
and Chinese Meishan breeds. The aim of crossing two 
separate breeds was to enhance the heterozygosity (having 
different variants of the same gene) of the hybrid offspring, 
thus avoiding repetition and easing the mapping of different, 
interconnected loci. It was thus an effort that largely built on 
the old breeding work at ABRO. In addition, the Edinburgh 
researchers acquired a computer system and adapted an 
existing database for mouse genome data to use for the 
PiGMaP project. Software (CRI-MAP) was developed with 
new statistical tools specifically for the purpose of analysing 
the linkage data sent electronically from the PiGMaP 
participants (the ELWW grew to 21 laboratories – including 
some outside Europe – by the end of the first round of CEC 
funding in 1994). The project was coordinated from the 
IAPGR-ERS, principally by Archibald and Haley. 
Part of the project was to develop techniques for future 
mapping of quantitative trait loci (QTL), genes thought to 
be relevant in economically important characteristics of 
livestock. This effort formed the main part of the second 
PiGMaP project (1994 to 1996), funded by the European 
Commission under the Third Framework Programme, and 
incorporating collaborators from 23 European laboratories. 
The Roslin scientists also collaborated with the French 
National Institute for Agronomic Research (INRA) on an 
informatics project (GEMINI: Genome Mapping Informatics 
Infrastructure, 1993 to 1995). This project was funded 
by the European Commission to develop databases and 
interfaces for the pig mapping initiative and the parallel, 
ongoing bovine genome work.13  Bazin was instrumental in 
encouraging this application to the BIOTECH-1 programme, 
just as he was in helping secure funding for the PiGMaP 
initiative. 
As well as PiGMaP, projects to map the pig genome were also 
underway in the US, at the Department of Agriculture Meat 
Animal Research Center in Nebraska, and there were also 
small Nordic and Sino-Danish collaborations. These networks 
cooperated with each other, to the point of establishing 
joint access and editorial responsibility for the PiGBASE 
data repository hosted in Roslin. They also compiled some 
consensus maps (Archibald et al, 1995; Rohrer et al, 1997), 
though no overall map integrating all of the linkage data of 
the various projects was produced. 
A key figure in encouraging genomic work in Edinburgh was 
Grahame Bulfield. A mouse geneticist by background, he was 
based in another AFRC-owned institution in Edinburgh, the 
Poultry Research Centre, and became director of the ERS-
IAPGR and then the Roslin Institute since 1988. Bulfield was 
also a member of the ad hoc Strategy Group of the Human 
Genome Mapping Project (HGMP), the first co-ordinated 
effort to produce a physical map of the human genome in 
the UK. In 1991, he wrote a lead article in the IAPGR annual 
report, stating that genomics should be the new frontier of 
animal genetics for the 21st century. Bulfield initially believed 
that Roslin should follow a ‘twin-track’ strategy in which the 
genomic techniques would identify suitable genes to produce 
transgenic animals. However, as time went by the PiGMap 
and parallel poultry and bovine genome efforts developed 
as autonomous ramifications of the pharming project, 
following a similar pattern to that of nuclear transfer and its 
application to regenerative medicine.14
Bulfield’s role boosted collaboration between pig and 
human genome scientists. Researchers from the HGMP 
were invited to pig genome mapping meetings, and the 
techniques and standards employed in human genome 
mapping were adopted and adapted by the pig genome 
mapping community, for instance by using the same 
nomenclature and adhering to the Bermuda Principles, Fort 
Lauderdale agreement and the Toronto statement (Archibald 
et al, 2010). The increasingly comprehensive maps of 
human genes and human DNA sequences were used as an 
important basis of comparison for the pig mappers, and 
probes containing human DNA were used to identify markers 
in the pig genome. Comparisons took advantage of the 
evolutionary relatedness of humans and pigs, and therefore 
the relative similarity of their DNA.
In the late 1990s, the scientists involved in the genetic and 
physical mapping of the pig genome turned their attention 
to the prospect of sequencing, i.e. producing a full catalogue 
of the linear structure – the sequence – of chemical units 
integrating the pig DNA. At first, this was under the auspices 
of an ‘agricultural genome,’ a growing scientific and 
policy objective of that time in the US. Within a few years, 
however, the community had shifted its arguments towards 
sequencing the pig genome as a biomedical resource, as 
can be seen in the White Paper published by key figures in 
the pig genome research community in the US in 2002.15  
They cited the similarity between pigs and humans in their 
case. Although they were unsuccessful in securing funding 
from the National Institutes of Health for the project, the 
positioning of the pig as a biomedical model by members of 
13 The Third European Framework programme funded genomic initiatives on cow and chicken to run in parallel with the pig work. The bovine genome project was coordinated in France, while the poultry effort 
was led by David Burt and Paul Hocking in Roslin (Grahame Bulfield, personal communication).
14 On the HGMP, see García-Sancho (2016) and “Human Genome Mapping Project (HGMP) – Ad hoc Strategy Group.” Sydney Brenner’s Collection, Cold Spring Harbor Laboratory Archives, reference SB/4/1/267. 
On the development of farm animal genomics and its connection with the HGMP, G. Bulfield: “From the trait to the gene – animal breeding in the year 2000?” IAPGR – Annual Report 1990-91, pp. 118-19. 
Wellcome Trust Towards Dolly archival project, Edinburgh University Library Special Collections, reference EUA IN23/3/1/1.
15 Rohrer G, Beever JE, Rothschild MF, Schook L, Gibbs R and Weinstock G (2002) ‘Porcine Sequencing White Paper: Porcine Genomic Sequencing Initiative’ 
 https://www.genome.gov/pages/research/sequencing/seqproposals/porcineseq021203.pdf (last accessed May 2017).
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the genome community has continued (Groenen et al, 2012; 
Kuzmuk & Schook, 2011; Schook et al, 2005).
Eventually, funding for the Swine Genome Sequencing 
Consortium was acquired from several sources: the 
BBSRC and DEFRA in the UK; the European Union; the US 
Department of Agriculture; Iowa and North Carolina State 
Universities, and different industrial associations, such as 
the National Pork Board in the US. A physical map of the 
pig genome was produced, and four Bacterial Artificial 
Chromosomes – large pieces of DNA – from the Children›s 
Hospital Oakland Research Institute, INRA-Toulouse and 
the Roslin Institute were sent to the Wellcome Trust Sanger 
Institute in Hinxton, Cambridgeshire, for whole genome 
sequencing. Sequencing took place primarily at the Sanger 
from 2006 to 2009, and the compilation of the genome was 
conducted in part by comparison with the human genome 
through a variety of techniques and aided by WuBLASTn, a 
tool that allows researchers to identify genomic regions with 
similar sequences. 
16 Home Office (2016) Annual Statistics of Scientific Procedures on Living Animals, Great Britain 2015 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/537708/scientific-
procedures-living-animals-2015.pdf (last accessed May 2017).
17 This decline in the public image of agriculture is largely a consequence of the surpluses of food production that Western societies faced following post-World War II policies (Thirtle, et al., 1991). As a result, the 
European Common Agricultural Policy and other initiatives in the last third of the twentieth century have gradually shifted from production to productivity, this leading to biodiversity problems, difficulties in 
farming communities and new animal diseases such as PSS.
of sequenced genomes and their annotation has occurred 
much later for the pig than for other key species used as 
models in human medicine, such as the mouse. The ‘toolbox’ 
is therefore less well-equipped. Furthermore, the pig genome 
community has predominantly been integrated by animal 
geneticists, with links to livestock and breeding industries. 
They have fewer links to and awareness of the needs of the 
biomedical research community and the pharmaceutical 
industry. Ironically, in the UK at least, the pig scientists have 
been far more integrated into the networks and methods of 
human genome mapping and sequencing than other animal 
genomic researchers.
The development of farm animal genomics in Edinburgh 
presents similarities with nuclear transfer, in the sense 
that both technologies originated as tools to achieve the 
objectives of the pharming project. However, with the 
passage of time both genomic and cloning techniques 
moved away from animal genetic modification and into the 
realm of human medicine. This distancing from agriculture 
may be in part linked to the long-term consequences 
of the Rothschild reforms and the promotion of a 
neoliberally-inspired science that prioritises urban, individual 
anthropocentrism. Societies after the 1970s became 
less attached – both emotionally and economically – to 
farms and perceived food production through breeding as 
unimportant. 17
At a practical level, this anthropocentric shift makes Dolly’s 
legacy difficult to capture from a BBSRC perspective. The very 
name BBSRC, adopted in 1994, left agriculture outside the 
acronym. This seems at odds with the council’s institutional 
predecessors, the ARC and AFRC, which over more than 
fifty years showed a strong tradition of funding agricultural 
research. Moreover, regenerative and genomic medicine, 
the two areas where the pharming project leads in this 
report, are mainly under the auspices of the MRC today. The 
serendipitous pathway of Dolly and its transition from animal 
to human sciences highlights the limitations of capturing 
the past from a single-institutional lens, regardless of it 
being the MRC or the BBSRC in its current non-agricultural 
denomination. Historical research may help to overcome 
these barriers and document the legacy of long-term funding 
programmes that span across various administrations.
With the passage of time, 
both genomic and cloning 
techniques moved away from 
animal genetic modification 
and into the realm of human 
medicine.
The genome of the pig was published in Nature in 2012, in 
a paper analysing the evolutionary implications of the data, 
and attempting to demonstrate the usefulness of the pig for 
biomedical research (Groenen et al, 2012). Certain specialist 
breeds of pig, such as the Göttingen minipig, are becoming 
common in biomedical laboratories, and the use of pigs as 
animal models of disease as well as in regulatory procedures 
is increasing (Kuzmuk & Schook, 2011). The spread of the 
domestic pig (Sus scrofa) as a biomedical model is limited 
in the UK however, and much smaller than sheep (Ovis 
aries) and mouse (Mus musculus), the most commonly used 
animal.16 This is partly because of the existence of strict 
regulations governing the use of animals in research, which 
makes the pig an expensive animal to house and care for.
This biomedical connection continues to be an objective of 
the pig genome community today. However, the production 
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The findings of our research project, summarised in this 
report, suggest that a historical approach to science may 
help the planning activity of administrative and funding 
agencies. There is currently a convergence of interests that 
may stimulate collaboration between historians and science 
policy institutions. Academic historians are realising the 
importance of ‘following the money’ to capture long-term 
developments and patterns in science (Edgerton, 2012). This 
involves expanding the range of people to be historically 
investigated and focus not only on scientists, but also on 
administrators in charge of the day-to-day running of 
funding programmes (García-Sancho, 2016: 77ff). Science 
policy institutions, on their side, are facing a growing volume 
of interdisciplinary areas that need to be funded through 
collaborative work across the humanities, natural and 
social sciences. In the UK, research councils are increasingly 
issuing calls for proposals across their domains and their 
officers have adopted the practice of looking at the past and 
constructing narratives that document the impact of the 
programmes they fund.18
The case study we have presented shows the utility of 
history for documenting the impact of pharming, a research 
project that spanned across councils and lasted for more 
than a decade. Addressing pharming historically means 
investigating different incarnations of funding agencies 
and their support to scientific institutions that also changed 
significantly over time. Most of the transformations we have 
evidenced are embedded in the change of name of the 
institutions involved, for instance the 1994 shift from the 
Agricultural and Food Research Council (AFRC) to the current 
Biotechnology and Biological Sciences Research Council 
(BBSRC). More importantly, the legacy of the pharming 
project can be captured in Ian Wilmut’s career move from 
the BBSRC-funded Roslin Institute to the Medical Research 
Council Centre for Regenerative Medicine. History explains 
why these transitions occurred and, in so doing, assist 
research council officers to assess the impact of their fields 
beyond their institutional confort zones. A BBSRC officer 
may discover through our investigation that Dolly’s cloning 
technique was crucial for the development of human stem 
cell research. Conversely, the MRC may find in agricultural 
rather than medical research the origins of cell therapy, one 
of its most promising funding areas today.19
4. Conclusion: history in research planning and policy
Historical research may, thus, provide an inter-institutional 
lens that helps documenting and analysing long-term 
impact. Overall, our case study shows the importance of 
sustained funding beyond the usual three-year grant limits. 
The continued support of the AFRC and later the BBSRC 
to the Roslin scientists was essential for the key medical 
contributions that their research delivered and continues to 
deliver today. Ironically, these contributions did not develop 
according to plan and the research project within which 
Dolly was created – pharming – never fulfilled its stated 
objectives. This could be interpreted as a failure if the project 
is addressed from a narrow single-institutional perspective. 
However, if the MRC – as well as the BBSRC – is taken into 
the equation, a rich genealogy can be established between 
animal breeding and regenerative medicine, one that has the 
potential to inspire future cross-council initiatives.
18 Cross-council areas of research (http://www.rcuk.ac.uk/research/xrcprogrammes/) and an example of the BBSRC impact case studies: http://www.bbsrc.ac.uk/news/impact/ (last accessed May 2017).
19 This capacity of looking beyond institutional boundaries will become crucial in UK Research and Innovation, the new institution that will integrate the seven British research councils (see 
https://www.gov.uk/government/news/sir-mark-walport-will-lead-uk-research-and-innovation and https://www.parliament.uk/business/committees/committees-a-z/commons-select/science-and-technology-
committee/inquiries/parliament-2015/inquiry1/, last accessed May 2017).
20 In 2012, the Wellcome Trust funded the project Towards Dolly to catalogue the records of the Roslin Institute and its predecessor organisations: 
http://archives.collections.ed.ac.uk/repositories/2/resources/85710 and http://libraryblogs.is.ed.ac.uk/towardsdolly/ (last accessed May 2017). This and the records of the BBSRC at the National Archives 
– along with some uncatalogued files held at its headquarters in Swindon – have been the main sources of our research.
Historical research may 
provide an inter-institutional 
lens that helps documenting 
scientific impact beyond the 
administrative boundaries of 
funding agencies.
The availability of archives that document those often 
serendipitous trajectories is crucial for historical research.20 
Apart from archival sources, a crucial piece of evidence for 
our work was the Collective Memory Event we organised 
half-way through the project. Inspired in an established 
tradition of witness seminars in the history of medicine 
(Tansey, 2006; Tansey, 2008), this event gathered the joint 
recollections of ten key players involved in the creation of 
Dolly. The participants included not only academic scientists, 
but also institutional managers, technicians and actors from 
the corporate world (Myelnikov & Garcia-Sancho, 2017). 
Their juxtaposed memories provided a unique picture of 
the intricacy of the experiments that preceeded the birth 
of the sheep, her overwhelming publicity and unexpected 
legacy. This technique could be fruitfully commissioned by 
the BBSRC or other research councils to document the history 
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and long-term impact of strategic areas. In our project, it 
has also fostered interdisciplinary collaborations with the 
researchers at Roslin, exemplified by a show we jointly 
organised at the Edinburgh Fringe Festival in August 2016 
with occasion of the twentieth anniversary of the birth of 
Dolly.21 
Rather surprisingly, the participants in the Collective Memory 
Event expressed doubts about the feasibility today of a 
project like the one that delivered Dolly (Myelnikov & Garcia-
Sancho, 2017: 38ff). The short-termism of research grants 
and postdoctoral contracts make impossible a multi-decade 
research project that, like pharming, started with animal 
breeding in the 1980s and finished with human stem cells in 
the 21st century. Such a programme could also be deemed 
unsuccessful, since it did not deliver the outcomes that were 
stated in the original application. A look into the past through 
this type of events may, thus, inform the future and prevent 
linear and short-sighted science policy-making.
21 See trailer of the Fringe show (https://www.youtube.com/watch?v=LClmL5C9YJE&t=1s) and electronic version of the Collective Memory Event: 
http://www.research.ed.ac.uk/portal/en/publications/dolly-at-roslin-a-collective-memory-event(59056ace-04a4-4019-b033-936cd7297f71).html (last accessed May 2017).
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